Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 16302795)

1.

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A.

Osteoporos Int. 2015 Feb;26(2):699-712. doi: 10.1007/s00198-014-2944-6. Epub 2014 Nov 29.

2.

3-Cyano-3-aza-β-amino Acid Derivatives as Inhibitors of Human Cysteine Cathepsins.

Schmitz J, Beckmann AM, Dudic A, Li T, Sellier R, Bartz U, Gütschow M.

ACS Med Chem Lett. 2014 Aug 11;5(10):1076-81. doi: 10.1021/ml500238q. eCollection 2014 Oct 9.

PMID:
25313316
3.

Chondroitin sulfate promotes activation of cathepsin K.

Lemaire PA, Huang L, Zhuo Y, Lu J, Bahnck C, Stachel SJ, Carroll SS, Duong le T.

J Biol Chem. 2014 Aug 1;289(31):21562-72. doi: 10.1074/jbc.M114.559898. Epub 2014 Jun 23.

PMID:
24958728
4.

Reversible cysteine protease inhibitors show promise for a Chagas disease cure.

Ndao M, Beaulieu C, Black WC, Isabel E, Vasquez-Camargo F, Nath-Chowdhury M, Massé F, Mellon C, Methot N, Nicoll-Griffith DA.

Antimicrob Agents Chemother. 2014;58(2):1167-78. doi: 10.1128/AAC.01855-13. Epub 2013 Dec 9.

5.

Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits.

Pennypacker BL, Oballa RM, Levesque S, Kimmel DB, Duong le T.

BMC Musculoskelet Disord. 2013 Dec 9;14:344. doi: 10.1186/1471-2474-14-344.

6.

Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Duong le T.

Bonekey Rep. 2012 May 2;1:67. doi: 10.1038/bonekey.2012.67. eCollection 2012.

7.

Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.

Zerbini CA, McClung MR.

Ther Adv Musculoskelet Dis. 2013 Aug;5(4):199-209. doi: 10.1177/1759720X13490860.

8.

Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target.

Choy JW, Bryant C, Calvet CM, Doyle PS, Gunatilleke SS, Leung SS, Ang KK, Chen S, Gut J, Oses-Prieto JA, Johnston JB, Arkin MR, Burlingame AL, Taunton J, Jacobson MP, McKerrow JM, Podust LM, Renslo AR.

Beilstein J Org Chem. 2013;9:15-25. doi: 10.3762/bjoc.9.3. Epub 2013 Jan 4.

9.

Potential role of odanacatib in the treatment of osteoporosis.

Ng KW.

Clin Interv Aging. 2012;7:235-47. doi: 10.2147/CIA.S26729. Epub 2012 Jul 12. Review.

10.

Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells.

Cartledge DM, Colella R, Glazewski L, Lu G, Mason RW.

Invest New Drugs. 2013 Feb;31(1):20-9. doi: 10.1007/s10637-012-9826-6. Epub 2012 May 2.

11.

New approaches for dissecting protease functions to improve probe development and drug discovery.

Deu E, Verdoes M, Bogyo M.

Nat Struct Mol Biol. 2012 Jan 5;19(1):9-16. doi: 10.1038/nsmb.2203. Review.

12.

The subcellular distribution of small molecules: from pharmacokinetics to synthetic biology.

Zheng N, Tsai HN, Zhang X, Rosania GR.

Mol Pharm. 2011 Oct 3;8(5):1619-28. doi: 10.1021/mp200092v. Epub 2011 Aug 15. Review.

13.
14.

Cathepsin K inhibitors for osteoporosis and potential off-target effects.

Brömme D, Lecaille F.

Expert Opin Investig Drugs. 2009 May;18(5):585-600. doi: 10.1517/13543780902832661 . Review.

15.

Simulation-based cheminformatic analysis of organelle-targeted molecules: lysosomotropic monobasic amines.

Zhang X, Zheng N, Rosania GR.

J Comput Aided Mol Des. 2008 Sep;22(9):629-45. doi: 10.1007/s10822-008-9194-7. Epub 2008 Mar 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk